Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Today, Barclays raised its price target on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to $8.00 per share.
There are 6 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Buy with a consensus target price of $12.2143 per share, a potential 46.63% upside.
Some recent analyst ratings include
- 11/16/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has coverage initiated with a Overweight ➝ Overweight rating and $15.00 price target
- 8/13/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Buy rating reiterated by HC Wainwright with a $13.00 price target
- 8/9/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Buy rating reiterated by Jefferies Financial Group with a $8.50 price target
- 8/8/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has coverage initiated with a Overweight rating and $9.00 price target
- On 3/12/2019 Steve Aselage, Director, bought 2,000 with an average share price of $8.30 per share and the total transaction amounting to $16,600.00.
- On 1/28/2019 Lynne Powell, VP, sold 12,000 with an average share price of $9.75 per share and the total transaction amounting to $117,000.00.
- On 1/28/2019 Thomas R Staab II, CFO, sold 5,000 with an average share price of $9.85 per share and the total transaction amounting to $49,250.00.
- On 1/25/2019 Lynne Powell, VP, sold 6,000 with an average share price of $9.60 per share and the total transaction amounting to $57,600.00.
- On 1/18/2019 Lynne Powell, VP, sold 2,000 with an average share price of $9.40 per share and the total transaction amounting to $18,800.00.
- On 1/16/2019 Lynne Powell, VP, sold 3,046 with an average share price of $9.27 per share and the total transaction amounting to $28,236.42.
- On 1/14/2019 Lynne Powell, VP, sold 954 with an average share price of $9.20 per share and the total transaction amounting to $8,776.80.
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Recent Trading Activity for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Shares of BioCryst Pharmaceuticals, Inc. closed the previous trading session at 8,33 +0,19 2,33 % with 8.1 shares trading hands.